Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Osteocalcin anticorps (N-Term)

BGLAP Reactivité: Humain WB, IHC (p), EIA Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN357367
  • Antigène Voir toutes Osteocalcin (BGLAP) Anticorps
    Osteocalcin (BGLAP)
    Épitope
    • 15
    • 10
    • 9
    • 8
    • 8
    • 7
    • 7
    • 7
    • 6
    • 6
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 9-39, N-Term
    Reactivité
    • 100
    • 43
    • 21
    • 20
    • 19
    • 15
    • 15
    • 10
    • 8
    • 7
    • 4
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 91
    • 32
    • 2
    • 2
    • 1
    Lapin
    Clonalité
    • 95
    • 33
    Polyclonal
    Conjugué
    • 74
    • 13
    • 11
    • 8
    • 6
    • 5
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp Osteocalcin est non-conjugé
    Application
    • 96
    • 71
    • 50
    • 15
    • 15
    • 14
    • 14
    • 9
    • 8
    • 8
    • 8
    • 6
    • 5
    • 2
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
    Specificité
    This antibody detects Osteocalcin at N-term.
    Réactivité croisée (Details)
    Species reactivity (tested):Human.
    Purification
    Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
    Immunogène
    Synthetic peptide KLH conjugated between 9~39 amino acids from the N-terminal region of Human Osteocalcin.
    Isotype
    Ig Fraction
    Top Product
    Discover our top product BGLAP Anticorps primaire
  • Indications d'application
    ELISA: 1/1,000. Western blot: 1/100-1/500. Immunohistochemistry: 1/50-1/100.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.25 mg/mL
    Buffer
    PBS with 0.09 % (W/V) Sodium Azide as preservative
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Conseil sur la manipulation
    Avoid repeated freezing and thawing.
    Stock
    4 °C/-20 °C
    Stockage commentaire
    Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
  • Antigène
    Osteocalcin (BGLAP)
    Autre désignation
    Osteocalcin (BGLAP Produits)
    Synonymes
    anticorps BGP, anticorps OC, anticorps OCN, anticorps Bglap1, anticorps Bglap2, anticorps OG1, anticorps mOC-A, anticorps Bgp, anticorps Bgpr, anticorps Bgpra, anticorps bgp, anticorps LOC792433, anticorps ocn, anticorps GLA, anticorps BGLAP, anticorps PMF1, anticorps bone gamma-carboxyglutamate protein, anticorps bone gamma carboxyglutamate protein, anticorps bone gamma-carboxyglutamate protein S homeolog, anticorps bone gamma-carboxyglutamate (gla) protein, anticorps osteocalcin, anticorps polyamine-modulated factor 1, anticorps BGLAP, anticorps Bglap, anticorps bglap.S, anticorps bglap, anticorps ocn, anticorps LOC100529177, anticorps LOC100146589
    Sujet
    Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.Synonyms: BGLAP, Bone Gla protein, Gamma-carboxyglutamic acid-containing protein
    Poids moléculaire
    10962 Da
    ID gène
    632
    NCBI Accession
    NP_954642
    UniProt
    P02818
Vous êtes ici:
Support technique